From Name:
From Email:
To Name:
To Email:

Optional Message:

New combination therapy promising for triple-negative breast cancer

from Oncology Nurse Advisor

The investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2, an innovative, multidrug, phase 2 breast cancer trial, has yielded positive results with the first drug to complete testing during the trial. Adding the chemotherapy, carboplatin, and the molecularly targeted drug, veliparib, to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial, which were presented at the 2013 San Antonio Breast Cancer Symposium. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063